Drugs / AMP-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04541550 | Apr → Jul 2021 | hidradenitis suppurativa | IntegoGen, LLC | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-12-29 | Amphastar Pharmaceuticals, Inc. | Regulatory Amphastar Announces Approval for Glucagon for Injection Kit, 1mg amphastar.com ↗
Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. |
| 2018-10-09 | Evofem Inc. | Results Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress evofem.com ↗
Results from the acceptability questionnaire in AMP001 demonstrated that Amphora was the preferred choice of birth control method in women users over the 6-month study period and acceptability remained high after cycle 13. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-29 | Amphastar Pharmaceuticals, Inc. | Amphastar Announces Approval for Glucagon for Injection Kit, 1mg amphastar.com ↗ |
| 2018-10-09 | Evofem Inc. | Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress evofem.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04541550 ↗ |